At a glance
ClinicalIndex Comparison RecordN/ACompleted· 15 enrolled
Drug / intervention
Photocil for Vitiligo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study of Novel Topical Drug (Photocil) for the Treatment of Vitiligo
In Brief
A clinical study evaluating Photocil for Vitiligo and Placebo - Sunscreen (SPF 2) for Vitiligo. Completed, enrolled 15 participants across 1 site.
Detailed Summary
Photocil is a topical drug (cream) that selectively delivers Narrow Band - Ultraviolet B (NB-UVB) therapy when exposed to sunlight. Photocil is intended to help protect users from non-therapeutic Ultraviolet B (UVB) radiation while selectively passing wavelengths of light in the NB-UVB range with peak transmission of 308nm. The aim of the study is to assess the safety and efficacy of Photocil in the treatment of vitiligo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVitiligo
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartAug 2013
First PostedNov 2013
Primary CompletionDec 2014
TodayJul 2026
First PostedNov 25, 2013
Enrollment StartAug 1, 2013
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 12.6 years ago
Interventions
Photocil for Vitiligodrug
Photocil for Vitiligo
Placebo - Sunscreen (SPF 2)other
Placebo - Sunscreen (SPF 2)